Intel stock spikes after report of possible US government stake
Investing.com - Brookline Capital Markets has lowered its price target on IceCure Medical Ltd. (NASDAQ:ICCM) to $2.77 from $3.53 while maintaining a Buy rating on the stock. The medical device company’s shares currently trade at $0.81, down about 20% year-to-date, according to InvestingPro data.
The firm cited IceCure’s "mostly uneventful" second quarter, noting that the FDA has requested additional information regarding the post-marketing study submitted by the company in the first quarter of 2025.
This FDA request has pushed back potential approval for IceCure’s ProSense system to the end of the year, according to Brookline Capital’s analysis.
In Japan, Terumo expects to file for regulatory approval of ProSense in the second half of 2025, representing another key milestone for the medical device company.
Brookline Capital also highlighted IceCure’s financial position, noting that its cash balance of $5.4 million as of June 30, plus proceeds from a $10 million rights offering, should fund operations beyond FDA approval of ProSense, excluding potential additional funds from the exercise of outstanding warrants. While the company maintains minimal debt with a debt-to-equity ratio of just 0.06, InvestingPro analysis reveals 12 additional key insights about ICCM’s financial health and growth prospects, available in the comprehensive Pro Research Report.
In other recent news, IceCure Medical announced its first-quarter financial results, reporting revenue of $725,000, a slight 2% decline from the previous year but close to H.C. Wainwright’s projection of $750,000. The company posted a net loss of $3.6 million, or ($0.06) per share, which was narrower than the expected loss of $4.4 million. H.C. Wainwright maintained a Buy rating on the company, with a price target of $2.50. IceCure Medical has scheduled several shareholder meetings, including an Annual and Special General Meeting on August 20, 2025, and a Special General Meeting on September 1, 2025. Shareholders of record as of specified dates in July and August will be entitled to participate and vote in these meetings. The company also updated its proxy materials for the September meeting to include a website address for remote attendance. Additionally, IceCure Medical has submitted its post-market study plan to the FDA, an essential step for the De Novo marketing authorization for its ProSense treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.